- Home
- IOTR vs GBIO Comparison
IOTR vs GBIO Comparison
Compare IOTR & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOTR
- GBIO
- Stock Information
- Founded
- IOTR 2019
- GBIO 2016
- Country
- IOTR Singapore
- GBIO United States
- Employees
- IOTR N/A
- GBIO N/A
- Industry
- IOTR
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- IOTR
- GBIO Health Care
- Exchange
- IOTR NYSE
- GBIO Nasdaq
- Market Cap
- IOTR 29.5M
- GBIO 29.2M
- IPO Year
- IOTR 2025
- GBIO 2020
- Fundamental
- Price
- IOTR $0.47
- GBIO $0.38
- Analyst Decision
- IOTR
- GBIO Strong Buy
- Analyst Count
- IOTR 0
- GBIO 4
- Target Price
- IOTR N/A
- GBIO $7.33
- AVG Volume (30 Days)
- IOTR 651.9K
- GBIO 476.6K
- Earning Date
- IOTR 01-01-0001
- GBIO 05-07-2025
- Dividend Yield
- IOTR N/A
- GBIO N/A
- EPS Growth
- IOTR N/A
- GBIO N/A
- EPS
- IOTR N/A
- GBIO N/A
- Revenue
- IOTR $9,578,336.00
- GBIO $24,556,000.00
- Revenue This Year
- IOTR N/A
- GBIO N/A
- Revenue Next Year
- IOTR N/A
- GBIO N/A
- P/E Ratio
- IOTR N/A
- GBIO N/A
- Revenue Growth
- IOTR 13.93
- GBIO 146.47
- 52 Week Low
- IOTR $0.31
- GBIO $0.32
- 52 Week High
- IOTR $5.98
- GBIO $3.65
- Technical
- Relative Strength Index (RSI)
- IOTR N/A
- GBIO 45.45
- Support Level
- IOTR N/A
- GBIO $0.37
- Resistance Level
- IOTR N/A
- GBIO $0.41
- Average True Range (ATR)
- IOTR 0.00
- GBIO 0.03
- MACD
- IOTR 0.00
- GBIO 0.00
- Stochastic Oscillator
- IOTR 0.00
- GBIO 28.93
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.